Ausgabe 1/2013
Inhalt (27 Artikel)
Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent
Sang Joon Shin, Jee Won Hwang, Joong Bae Ahn, Sun Young Rha, Jae Kyung Roh, Hyun Cheol Chung
A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer
J. Rodríguez-Pascual, P. Sha, E. García-García, N. V. Rajeshkumar, E. De Vicente, Y. Quijano, A. Cubillo, B. Angulo, O. Hernando, M. Hidalgo
Inhibitors of cathepsins B and L induce autophagy and cell death in neuroblastoma cells
Donna M. Cartledge, Rita Colella, Lisa Glazewski, Guizhen Lu, Robert W. Mason
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
Brigette B. Y. Ma, Vivian W. Y. Lui, Crystal S. Cheung, Cecilia P. Y. Lau, Kakiu Ho, Edwin P. Hui, Stephen K. W. Tsui, Margaret H. Ng, S. H. Cheng, Patrick K. S. Ng, Sai Wai Tsao, Anthony T. C. Chan
Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines
Jodi A. Muscal, Kathleen A. Scorsone, Linna Zhang, Jeffrey A. Ecsedy, Stacey L. Berg
Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer
Nilesh A. Patankar, Dawn Waterhouse, Dita Strutt, Malathi Anantha, Marcel B. Bally
Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study
Anne Sudaka, Antoine Susini, Cristiana Lo Nigro, Jean-Louis Fischel, Nicolas Toussan, Patricia Formento, Federica Tonissi, Laura Lattanzio, Elvio Russi, Marie-Christine Etienne-Grimaldi, Marco Merlano, Gérard Milano
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases
Teresa G. Granda, David Cebrián, Sonia Martínez, Patricia Villanueva Anguita, Estela Casas López, Wolfgang Link, Teresa Merino, Joaquín Pastor, Beatriz G. Serelde, Sandra Peregrina, Irene Palacios, Maria Isabel Albarran, Antonio Cebriá, Milagros Lorenzo, Patricia Alonso, Jesús Fominaya, Ana Rodríguez López, James R. Bischoff
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso, Nicole D. Houston, Robert L. Coleman, Manuela Buzoianu, Gabriel Robbie, Robert Lechleider
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer
Sil Kordes, Dick J. Richel, Heinz-Josef Klümpen, Mariëtte J. Weterman, Arnoldus J. W. M. Stevens, Johanna W. Wilmink
Phase I trial of dasatinib and ixabepilone in patients with solid tumors
P. Herbolsheimer, R. Kapoor, K. L. Smith, D. Perry, N. Verma, I. Veytsman, J. Jelinek, S. M. Swain
A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma
Thomas Yau, P. N. Cheng, Pierre Chan, William Chan, Li Chen, Jimmy Yuen, Roberta Pang, S. T. Fan, Ronnie T. Poon
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours
Yasuhito Fujisaka, Yusuke Onozawa, Takayasu Kurata, Hirofumi Yasui, Isao Goto, Kentaro Yamazaki, Nozomu Machida, Junichiro Watanabe, Hitoshi Shimada, Xiaojin Shi, Narikazu Boku
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
A. Dasari, L. Gore, W. A. Messersmith, S. Diab, A. Jimeno, C. D. Weekes, K. D. Lewis, H. A. Drabkin, T. W. Flaig, D. R. Camidge
Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent
Matthew Burge, Alessandra B. Francesconi, Dusan Kotasek, Rosa Fida, Gregg Smith, Andrew Wilks, Paul A. Vasey, Jason D. Lickliter
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer
Glen J. Weiss, Ross C. Donehower, Tara Iyengar, Ramesh K. Ramanathan, Karen Lewandowski, Eric Westin, Karla Hurt, Scott M. Hynes, Stephen P. Anthony, Scott McKane
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma
Christopher W. Ryan, Chacon Matias, Mark Agulnik, Antonio Lopez-Pousa, Charles Williams, Dinesh P. de Alwis, Christopher Kaiser, Mary Alice Miller, Sabine Ermisch, Robert Ilaria Jr, M. L. Keohan
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer
Keun Seok Lee, In Hae Park, Byung-Ho Nam, Jungsil Ro
Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancer
Amanda F. Baker, Denise J. Roe, Cynthia Laughren, Janice L. Cohen, Heather M. Wright, Mary C. Clouser, Haiyan Cui, David S. Alberts, Setsuko K. Chambers
Pemetrexed in patients with refractory soft tissue sarcoma: A non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005
J. T. Hartmann, S. Bauer, G. Egerer, M. S. Horger, H.-G. Kopp, V. Grünwald, F. Mayer
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
Christian Manegold, Johan Vansteenkiste, Felipe Cardenal, Wolfgang Schuette, Penella J. Woll, Ernst Ulsperger, Anne Kerber, Josef Eckmayr, Joachim von Pawel
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
Yong Sang Hong, Jeeyun Lee, Kyu-pyo Kim, Jae-Lyun Lee, Young Suk Park, Joon Oh Park, Se Hoon Park, Sun Young Kim, Ji Yeon Baek, Jee Hyun Kim, Keun-Wook Lee, Tae-You Kim, Tae Won Kim
The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice
Valentina Rapozzi, Sonia Zorzet, Marina Zacchigna, Sara Drioli, Luigi E. Xodo
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications
Antonio Garcia-Gomez, Enrique M. Ocio, Atanasio Pandiella, Jesús F. San Miguel, Mercedes Garayoa
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel
Alexander N. Wein, Shihui Liu, Yi Zhang, Andrew T. McKenzie, Stephen H. Leppla
Investigational agents in development for the treatment of ovarian cancer
Shannon N. Westin, Thomas J. Herzog, Robert L. Coleman
Development of artemisinin compounds for cancer treatment
Henry C. Lai, Narendra P. Singh, Tomikazu Sasaki